RevelleCare will merge compounded estrogen therapy with modern luxury skincare — designed for the 12+ million Canadian women navigating perimenopause and menopause. Launching Fall 2026 in Ontario & British Columbia.
The Planned Model
When RevelleCare launches in Fall 2026, care will be delivered in three simple steps — from your first consultation to your door.
You will answer a brief intake about your skin, hormonal health, and goals. Our clinical questionnaire will screen for candidacy in minutes.
A licensed Canadian physician will review your profile via telemedicine. If indicated, they will prescribe your personalized formulation.
Your compounded prescription will be dispensed by a licensed Canadian pharmacy and delivered to your door. Ongoing monitoring and renewal will be included.
Please note: RevelleCare is currently in pre-launch development. The service model described above represents our planned offering, pending Health Canada regulatory review, physician partnerships, and compounding pharmacy agreements. No products or services are currently available for purchase or prescription.
The Planned Collection
Each product will be compounded to pharmaceutical standards, prescribed by a licensed physician, and calibrated for menopausal skin biology. Not yet available.
Estradiol 0.01% · Estriol 0.3%
Will restore epidermal thickness and dermal collagen density. Based on clinical evidence showing up to 75% increase in skin thickness and 61–100% wrinkle reduction with these actives.
Learn more
Tretinoin 0.05% · Estriol 0.03%
Will accelerate cellular renewal while estriol supports barrier function. Formulated to address fine lines, uneven texture, and overnight skin repair simultaneously.
Learn more
Vitamin B3 · Vitamin C · Vitamin E · Peptides
A high-performance companion for those who prefer non-hormonal support. Antioxidant-rich with collagen-stimulating peptides for visible renewal.
Learn more"Where prescription science, modern luxury, and menopause care come together."
— Michèle Lunney, Founder & CEO
Our Founder
Founder & CEO, RevelleCare
With nearly two decades at the intersection of healthcare, innovation, and highly regulated sectors, Michèle built her career around growth strategy, commercialization, and high-value partnerships.
She founded RevelleCare to create a new category in women's health — one that finally gives menopausal skin the clinical precision it deserves, wrapped in an experience worthy of the women it serves.
Understanding the Transition
Estrogen is the primary regulator of skin collagen, hydration, and cell turnover. As levels drop during perimenopause, skin loses up to 30% of its collagen in the first five years.
Reduced estrogen compromises the skin barrier, leading to increased transepidermal water loss, sensitivity, and impaired healing — changes that standard moisturizers cannot fully address.
Only prescription-strength topical estrogen can act on dermal estrogen receptors — the site of collagen synthesis and elastin production. RevelleCare's planned formulations are designed to address what over-the-counter products simply cannot.
Join the RevelleCare waitlist and be notified the moment we open in Ontario & British Columbia. No obligation. No spam.
Launching Fall 2026 · Ontario & British Columbia first · National expansion to follow